Adnexus Therapeutics to Present at Thomas Weisel Partners Healthcare Conference.WALTHAM, Mass. -- Adnexus Therapeutics(TM), Inc. today announced its presentation at the Thomas Weisel Partners Thomas Weisel Partners Group, Inc. (NASDAQ: TWPG), often shortened to just TWP or TWeisel, is a U.S. middle-market and growth focused investment banking firm based in San Francisco, California. Healthcare Conference at the Four Seasons Hotel in Boston on Wednesday, September 6, 2006 at 11:30 a.m. Eastern Time. John Mendlein Dr. John Mendlein is a biotech executive and currently CEO of Adnexus Therapeutics, a Boston, MA based biotech company. He was formerly CEO of Affinium Pharmaceuticals. External links
About the New Adnectin Product Class and the PROfusion System Adnectins are an emerging protein therapeutic class that can be designed to address a broad range of diseases. They are based on human fibronectin, an extracellular extracellular /ex·tra·cel·lu·lar/ (-sel´u-lar) outside a cell or cells. ex·tra·cel·lu·lar adj. Located or occurring outside a cell or cells. protein that is naturally abundant in human serum. The intrinsic properties of an Adnectin align with the properties needed to make a successful drug, including high potency, specificity, stability, favorable half life, and high yield production. These and other important characteristics are predictable for the Adnectin product class, which greatly accelerates Adnectin drug discovery and development. Adnectins are designed using the PROfusion(TM) System, Adnexus' patented protein design engine, to achieve high potency and specificity for a therapeutic target while simultaneously selecting for ideal pharmaceutical product characteristics. PROfusion enables Adnexus to screen over 1 trillion unique Adnectins for each target to "redirect" a naturally occurring human fibronectin to act as a protein therapeutic. Adnexus is the exclusive developer of Adnectins. Adnexus solely owns the Adnectin patent estate that controls issued and pending patent properties to fundamental Adnectin forms. In addition, Adnexus exclusively controls its patented PROfusion System. Adnexus has over 100 issued and pending patent properties relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc Adnectins and PROfusion. About Adnexus Therapeutics Adnexus Therapeutics is focused on generating vital medicines through the discovery, development, and commercialization of its broadly applicable new therapeutic class, Adnectins. Adnexus lead product candidate, CT-322, is in Phase 1 clinical development. The company also has a pipeline of other Adnectin products in preclinical preclinical /pre·clin·i·cal/ (-klin´i-k'l) before a disease becomes clinically recognizable. pre·clin·i·cal adj. 1. research across multiple therapeutic areas. Adnectins are designed and optimized using PROfusion, the company's patented protein design engine that uniquely enables rapid optimization of protein therapeutics. The company is funded by four leading venture capital firms Name Location Founding date Managing Partners/Directors Specialty Capital managed 5AM Ventures Menlo Park, CA; Waltham, MA 2002 John Diekman, PhD (managing partner), Scott Rocklage, PhD (managing partner), Andrew Schwab (managing partner) life sciences $200M [1] : Atlas Venture Atlas Venture is an international early-stage venture capital firm that invests in communications, information technology, and life sciences companies. Atlas Venture has investing offices in Boston, London, Munich, and Paris, and its investments are evenly divided between the , Flagship Ventures, Polaris Venture Partners, and Venrock Associates. This news release contains certain forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. that involve risks and uncertainties. Such statements are only predictions and the company's actual results may differ materially from those anticipated in these forward-looking statements. Factors that may cause such differences include the timing of clinical trials, the risk that products that appeared promising in early research and clinical trials do not demonstrate safety or efficacy in clinical trials and the risk that the company will not obtain approval to market its products. Adnectin(TM), Adnexus Therapeutics(TM) and PROfusion(TM) are trademarks of Adnexus Therapeutics(TM), Inc. Adnexus Therapeutics(SM) is a service mark of Adnexus Therapeutics(TM). For more information, please visit www.adnexustx.com |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion